| 000 | 01525 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250515041804.0 | ||
| 264 | 0 | _c20070620 | |
| 008 | 200706s 0 0 eng d | ||
| 022 | _a1470-269X | ||
| 024 | 7 |
_a10.1038/sj.tpj.6500417 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWadelius, M | |
| 245 | 0 | 0 |
_aPharmacogenetics of warfarin: current status and future challenges. _h[electronic resource] |
| 260 |
_bThe pharmacogenomics journal _cApr 2007 |
||
| 300 |
_a99-111 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
| 650 | 0 | 4 |
_aBiotransformation _xgenetics |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C9 |
| 650 | 0 | 4 | _aGene Expression Regulation, Enzymologic |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 |
_aMixed Function Oxygenases _xgenetics |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVitamin K _xantagonists & inhibitors |
| 650 | 0 | 4 | _aVitamin K Epoxide Reductases |
| 650 | 0 | 4 |
_aWarfarin _xadministration & dosage |
| 700 | 1 | _aPirmohamed, M | |
| 773 | 0 |
_tThe pharmacogenomics journal _gvol. 7 _gno. 2 _gp. 99-111 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.tpj.6500417 _zAvailable from publisher's website |
| 999 |
_c16562337 _d16562337 |
||